ROR1 plays a critical role in pancreatic tumor-initiating cells with a partial EMT signature.
M. Yamazaki, S. Hino, S. Usuki, Y. Miyazaki, T. Oda, M. Nakao, T. Ito, K. Yamagata
Abstract
Tumor-initiating cells are the major drivers of chemoresistance and relapse, making them attractive targets for cancer therapy. However, the identity of tumor- initiating cells in human pancreatic ductal adenocarcinoma (PDAC) and the key molecules underlying their traits remain poorly understood. Here, we show that a partial epithelial-mesenchymal transition (EMT)-like subpopulation marked by high expression of receptor tyrosine kinase-like orphan receptor 1 (ROR1) is the origin of heterogeneous tumor cells in PDAC. We demonstrate that ROR1 depletion suppresses tumor growth, recurrence after chemotherapy, and metastasis. Mechanistically, ROR1 induces the expression of AURKB by activating E2F to enhance PDAC proliferation. Furthermore, epigenomic analyses reveal that ROR1 is transcriptionally dependent on YAP/BRD4 binding at the enhancer region, and targeting this pathway reduces ROR1 expression and prevents PDAC growth. Collectively, our findings reveal a critical role of ROR1high cells as tumor-initiating cells and the functional importance of ROR1 in PDAC progression, thereby highlighting its therapeutic targetability. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=192 HEIGHT=200 SRC="FIGDIR/small/499868v2_ufig1.gif" ALT="Figure 1"> View larger version (38K): org.highwire.dtl.DTLVardef@167bf72org.highwire.dtl.DTLVardef@49df52org.highwire.dtl.DTLVardef@1e480a3org.highwire.dtl.DTLVardef@b987bf_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- ROR2 regulates cellular plasticity in pancreatic neoplasia and adenocarcinoma
S. Benitz, A. Steep, … H. C. Crawford·bioRxiv·Dec 13, 2023
- Regulator of Chromosome Condensation (RCC1) a novel therapeutic target in pancreatic ductal adenocarcinoma drives tumor progression via the c-Myc-RCC1-Ran axis
S. F. Bannoura, A. Aboukameel, … A. S. Azmi·bioRxiv·Dec 18, 2023
- RhoV Promotes Proliferation, Migration, and MAPK Activation in Pancreatic Ductal Adenocarcinoma
Shang Wu, Jia Feng, … Shuai Lü·American Journal Of PathologyPeer-reviewed·Feb 26, 2026
- Presence of NCOR1+/CD4+ T cells in tertiary lymphoid organ predicts favorable prognosis in pancreatic ductal adenocarcinoma
- ADT-1004: A First-in-Class, Orally Bioavailable Selective pan-RAS Inhibitor for Pancreatic Ductal Adenocarcinoma
Dhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, … Bassel F. El‐Rayes·Molecular CancerPeer-reviewed·Mar 13, 2025
- NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer
J. Doffo, S. A. Bamopoulos, … M. Wirth·bioRxiv·Oct 21, 2021